Sabon Farfesa na Farko na Farfesa na Farko da Farfesa na Farko MS
Ocrevus anticlonal Ocrevus (ocrelizumab) shi ne FDA-yarda don zalunta duka MS na gaba da MSPS da kuma relaying MS. Wannan babbar nasara ta MS, kamar yadda babu wani magani don magance mutanen da ke fama da cutar ci gaba.
Menene Ocrevus?
Ocrevus (ocrelizumab) wani ɓangare ne wanda yake da alaka da kwayoyin halitta wanda ake kira CD20, wanda ya kasance akan farfajiyar sel na B (wani irin tsarin kwayoyin cuta).
Ta jingina zuwa CD20, adadin ƙwayoyin B an rage a jini.
Tunda kwayoyin B suna taka rawar a cikin asarar ƙirar ƙirar lalacewa da lalacewa a cikin ƙwayar sclerosis, an lalata waɗannan sassan B wanda aka nuna don rage yawan cututtukan MS. Wannan ake magana, saboda Ocrevus kawai yana ƙaddamar da ƙwayoyin B, wasu kwayoyin halitta a cikin tsarin da ba a rigakafi (kamar su T) sun kasance a cikin lalacewa, suna taimakawa wajen kula da aikin rigakafin mutum.
Ocrevus a cikin matakai na III na gwaji MS
Ocrevus an bincika cikin gwaje-gwaje na uku na III don magance duka komawa MS da kuma MS na gaba. A cikin gwaji guda biyu, Ocrevus aka kwatanta da Rebif don magance mutane tare da MS-remiting-remitting MS. Tun da yake babu wani magani da aka yarda da FDA ga MS-MS na gaba, Ocrevus an kwatanta shi da placebo a wannan gwaji.
Bayanan tunatarwa-yayin da gwajin gwaji na biyu ya bincika lafiyar da amfani da kwayoyi, lokuta na uku jarrabawa sun fi girma kuma sun kwatanta miyagun ƙwayoyi zuwa daidaito na miyagun ƙwayoyi.
Yin Magana da Sauke MS tare da Ocrevus
A cikin lokuta na uku na gwajin mutane tare da komawa MS, fiye da 1600 mahalarta sun kasance bazuwar don samun kofar Ocrevus a kowane watanni shida ko Rebif (interferon beta-1a) sau uku a mako ɗaya na tsawon makonni 96 (kusan shekaru biyu). Rebif wata magungunan cututtuka ne, ma'ana an ba shi a karkashin fata tare da allurar bakin ciki.
Sakamakon ya nuna cewa sake komawar shekara daya daga kashi 46 zuwa 47 cikin wadanda suka karbi Ocrevus fiye da wadanda suka karbi Rebif. Bugu da ƙari, an ƙaddamar da ci gaba da rashin lafiyar mahalarta a makonni 12 da makonni 24 ta amfani da sikelin EDSS .
A lokuta biyu, masu halartar taron da suka karbi Ocrevus suna ci gaba da rashin lafiyar marasa lafiya fiye da waɗanda suka karbi Rebif.
Har ila yau, akwai cututtukan gadolinium na 94 zuwa 95 bisa MRI a cikin kungiyar Ocrevus fiye da kungiyar Rebif.
Abubuwa masu ban tsoro a cikin waɗannan gwaje-gwajen biyu sun haɗa da:
- Hanyoyin haɗarin jigilar a cikin ƙungiyar Ocrevus (a cikin kadan fiye da kashi uku na mahalarta): kamar rash, flushing, ko itchiness
- Magunguna masu tsanani sun faru a kashi 1.3 cikin wadanda ke cikin kungiyar Ocrevus da kashi 2.9 a cikin kungiyar Rebif
- Sabbin sababbin nau'o'in nama (wanda ake kira neoplasms) ya faru a cikin kashi 0.5 na wadanda ke cikin kungiyar Ocrevus da kashi 0.2 a cikin rukunin Rebif.
Kula da Firayim na Farko-Mikiyar MS tare da Ocrevus
A cikin wani gwaji na III na Ocrevus a MS- MSM na gaba-gaba, (PPMS), fiye da 700 masu karbi sun karbi ko Ocrevus ko jigon wuribo kowane watanni 6 na akalla makonni 120.
Sakamakon ya nuna cewa a makonni 12, akwai ragowar kashi 24 cikin ci gaba da ci gaba da nakasa a cikin mahalarta wadanda suka karbi Ocrevus, a matsayin tsayayya da wadanda suka karbi wuri mai girama.
A makonni 24, ci gaba da rashin daidaito a jiki ya rage kashi 25 cikin dari a cikin mahalarta wadanda suka dauki Ocrevus.
An samo Ocrevus don rage lokacin da ya kamata masu halartar tafiya kashi 25 da kusan kashi 30 cikin dari idan aka kwatanta da jinsin wuribo.
A kwakwalwa MRI, bayan makonni 120, akwai kashi 3.4 cikin dari na ƙara yawan tarin ƙwayar cutar ta T2-hyperintense a cikin kungiyar Ocrevus tare da kashi 7.4 cikin dari na raunuka a cikin rukuni na placebo.
Dangane da mummunar tasiri, ƙungiyar Ocrevus tana da halayen haɗari masu haɗari, ƙananan cututtuka na numfashi na sama, da kuma cututtuka na cututtuka na kwakwalwa. Hakanan halayen haɗuwa (kamar rash, itching, flushing, da kuma bakin haushi) sun fi kowa bayan jigilar farko da kuma inganta tare da sauran kwayoyin.
Magunguna masu tsanani sun faru a kashi 6.2 cikin dari na kungiyar Ocrevus da kuma kashi 5.9 bisa dari na rukuni na placebo-don haka kama da bangarorin biyu. Masu bincike sun bayyana ainihin abin da mai tsanani ya kamu da ita-wata kamuwa da cuta wadda ta kamu da rai, hadarin rai, da ake bukata a asibiti, ya haifar da nakasa, ko buƙatar likita da ake buƙata (kamar maganin maganin rigakafi) don hana mutuwa ko rashin lafiya.
Yana da ban sha'awa a lura cewa akwai wasu ƙwayoyin cuta a cikin kungiyar Ocrevus (kamar nono da ciwon daji) fiye da rukuni. Babu tabbacin dalilin da ya sa wannan lamari ne da kuma bada ƙarin bincike.
Kalma Daga
Ocrevus (ocrelizumab) shine magani na farko na FDA don magance magunguna na farko, MS, wanda ke rinjayar kusan 10 zuwa 15 bisa dari na mutanen da ke tare da MS, saboda haka wannan yana da ban sha'awa sosai. Tabbas, yana da mahimmanci ga waɗanda suke tare da nau'in MS, kamar yadda mutane da yawa sun ci gaba da bunkasa sakewa duk da maganin MS na yanzu. Ocrevus yanzu yana ba su wani zaɓi.
Duk abin da ake faɗi, yana da muhimmanci a tuna cewa zabar maganin MS na lafiya a gare ku abu ne mai mahimmanci. Bugu da ƙari, sakamakon gwaje-gwaje uku a kan Ocrevus bazai yi la'akari da yadda za ku amsa maganin ba.
> Sources:
> Hauser SL et al. Ocrelizumab zuwa Interferon Beta-1a a relapsing multiple sclerosis. N Engl J Med . 2016 Dec 21.
> Montalban X et al. Ocrelizumab zuwa placebo a cikin matakai na farko na sclerosis. N Engl J Med. 2016 Dec 21.
> Sorensen PS, Blinkenberg M. Matsanancin tasiri ga ocrelizumab a lura da ƙwayar sclerosis mai yawa: shaida na yanzu da makomar gaba. Tsarancin Mara Neurol . 2016 Jan; 9 (1): 44-52.